PT  - JOURNAL ARTICLE
AU  - MASAKUNI SAKAGUCHI
AU  - TOSHIYA MAEBAYASHI
AU  - TAKUYA AIZAWA
AU  - NAOYA ISHIBASHI
AU  - TSUTOMU SAITO
TI  - Clinical Outcomes of Hypopharyngeal Cancer Receiving Definitive Radiotherapy with Concurrent Chemotherapy
DP  - 2017 Feb 01
TA  - Anticancer Research
PG  - 941--947
VI  - 37
IP  - 2
4099  - http://ar.iiarjournals.org/content/37/2/941.short
4100  - http://ar.iiarjournals.org/content/37/2/941.full
SO  - Anticancer Res2017 Feb 01; 37
AB  - Aim: To evaluate clinical outcomes of concurrent chemoradiotherapy (CCRT) in patients with hypopharyngeal cancer (HPC). Patients and Methods: This retrospective study included 80 patients (75 males) aged 48 to 78 years (median=66 years) with a histological diagnosis of HPC. The 5-fluorouracil and cisplatin (FP) regimen was used until 2007 and then switched to the docetaxel, cisplatin, and 5-fluorouracil (TPF) regimen. Radiotherapy was administered to a total dose of 60 to 72 Gy (median=66 Gy). Results: The 5-year overall survival and disease-free survival rates were 49.3% and 60.7%, respectively. Improved disease-free survival was associated with lower N-stage (hazard ratio=0.249; 95% confidence interval=0.096-0.643; p=0.041). Conclusion: There were no significant differences in overall and disease-free survival between patients receiving CCRT with the TPF regimen and those who received FP for a long period of treatment but did not finish two courses.